GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
112 articles in GLP-1 & Metabolic · page 6 of 10
GLP-1s and Mental Health: Untangling the Signals
Regulators found no causal link to suicidal thoughts, but the data still cannot promise mood neutrality for every individual.
Read →Can Training Offset GLP-1 Muscle Loss?
Resistance training is the obvious lever against lean-mass loss. What the evidence says it can protect on a GLP-1, and what it cannot.
Read →Cardiometabolic Risk: Where GLP-1s Fit
In SELECT (NEJM 2023), semaglutide cut major cardiovascular events 20% in high-risk adults. Where the class fits overall.
Read →Tolerance to GLP-1s: Does It Happen?
Does the body adapt and the weight effect fade? What multi-year semaglutide and tirzepatide trials actually show about it.
Read →GLP-1s and Insurance Coverage in 2026
Medicare's weight-loss exclusion, the temporary GLP-1 Bridge, 13 Medicaid states, and employer variation — the documented coverage picture, with dates.
Read →The History of Incretin Research, Briefly
From secretin in 1902 to tirzepatide in 2022: the verified dates and names behind the incretin story, and the long gaps between them.
Read →GLP-1s and Appetite Hormones: Leptin and Ghrelin
How GLP-1 drugs interact with the body's other hunger signals — leptin and ghrelin — and why appetite regulation is more than one hormone.
Read →How GLP-1s Slow Gastric Emptying
The mechanism behind both the fullness and the nausea on a GLP-1 — how much gastric emptying slows, and why the effect fades over time.
Read →GLP-1s and Eating Disorders: A Cautious Look
Appetite-suppressing drugs demand particular care here. What the limited eating-disorder evidence shows, and where the real risks sit.
Read →Why GLP-1 Trials Use Different Endpoints
Weight, A1c, cardiovascular events: what a GLP-1 trial measures shapes what its result can honestly claim. How to read the choice.
Read →GLP-1s in Adolescents: The Evidence and the Debate
In STEP TEENS, semaglutide cut BMI about 16% over 68 weeks. Efficacy is clear; long-term safety in growing bodies is not.
Read →The Durability Question: GLP-1s as Chronic Therapy
These look more like blood-pressure drugs than a course of antibiotics. Why that framing matters for how long people stay on them.
Read →